Carna Biosciences (TSE:4572) LT-Debt-to-Total-Asset: 0.57 (As of Dec. 2025)

What is Carna Biosciences LT-Debt-to-Total-Asset?

Carna Biosciences TSE:4572 +2.65% 34 LT-Debt-to-Total-Asset is 0.57 as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 34/100 and a GF Value™ of 円188.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Carna Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.57.

Carna Biosciences's long-term debt to total assets ratio increased from Dec. 2024 (0.01) to Dec. 2025 (0.57). It may suggest that Carna Biosciences is progressively becoming more dependent on debt to grow their business.

Carna Biosciences (TSE:4572) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Carna Biosciences LT-Debt-to-Total-Asset Related Terms

Carna Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences LT-Debt-to-Total-Asset Chart

Carna Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.04

0.01

0.57

Carna Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.29	0.57	0.99

34GF Score

Carna Biosciences Inc TSE:4572

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Carna Biosciences LT-Debt-to-Total-Asset Calculation

Carna Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	697.586	/	1229.648
	=	0.57

Carna Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	697.586	/	1229.648
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.57 mean?

Carna Biosciences (TSE:4572) has a LT-Debt-to-Total-Asset of 0.57 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Carna Biosciences and its competitors.

Is Carna Biosciences' LT-Debt-to-Total-Asset too high?

Carna Biosciences' current LT-Debt-to-Total-Asset is 0.57. Overall, Carna Biosciences has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Carna Biosciences' LT-Debt-to-Total-Asset compare to VRTX and REGN?

Carna Biosciences' LT-Debt-to-Total-Asset of 0.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current LT-Debt-to-Total-Asset is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Carna Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円188.38, compared to a current price of 円348.00 — trading 84.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.57. Carna Biosciences' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current LT-Debt-to-Total-Asset is 0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円348.00 is trading 84.7% above its estimated GF Value™ of 円188.38. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

LT-Debt-to-Total-Asset: 0.57
GF Value™: 円188.38 vs. price of 円348.00 (84.7% above fair value)
GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4880 TSE:4594 TSE:2385 TSE:520A TSE:2370 TSE:190A TSE:4584 TSE:4893 TSE:3750 TSE:4583 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047

Website http://www.carnabio.com

Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.

34GF Score

Get the complete analysis for TSE:4572

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円348.00

Price

円188.38

GF Value

View TSE:4572 Analysis

See LT-Debt-to-Total-Asset data for all stocks →